The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) for high-risk (HR) newly diagnosed multiple myeloma (NDMM): First-time report of the full cohort of transplant-eligible (TE) patients in the GMMG-CONCEPT trial.
 
Lisa Leypoldt
Honoraria - Abbvie; Adaptive Biotechnologies; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Pfizer; Sanofi; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Sanofi
Research Funding - Abbvie (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Oncopeptides; Sanofi
 
Varun Ginde
No Relationships to Disclose
 
Britta Besemer
Honoraria - AMGEN (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Oncopeptides (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AMGEN (Inst); Janssen Cilag (Inst); Janssen-Cilag
 
Marc Raab
Honoraria - Abbvie; Bristol-Myers Squibb/Celgene; Janssen; Sanofi
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; Janssen; Pfizer; Sanofi
 
Mathias Haenel
Honoraria - BMS GmbH & Co. KG; Falk Foundation; Gilead Sciences; Kite, a Gilead company; Novartis; SOBI
Consulting or Advisory Role - Amgen; Amgen; BeiGene; BMS GmbH & Co. KG; Janssen; Janssen; Janssen; Kite/Gilead; Kite/Gilead; Sanofi/Aventis
Travel, Accommodations, Expenses - Abbvie
 
Christoph Mann
Consulting or Advisory Role - BMS GmbH & Co. KG; Janssen; Sanofi
 
Christian Michel
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Oncopeptides
 
Hans Christian Reinhardt
Honoraria - Abbvie; Merck
Research Funding - Gilead Sciences
Other Relationship - CDL Therapeutics
 
Yon-Dschun Ko
No Relationships to Disclose
 
Igor Blau
No Relationships to Disclose
 
Christof Scheid
Employment - University of Cologne
Honoraria - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen Oncology; Novartis; Oncopeptides; Pfizer; Sanofi/Aventis; Stemline Therapeutics; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen Oncology; Roche; Sanofi/Aventis
Research Funding - Janssen Oncology (Inst); Novartis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology
 
Maike de Wit
Employment - Vivantes Network for Health
Speakers' Bureau - AstraZeneca; Janssen; Pierre Fabre; Sanofi
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genzyme (Inst); Janssen (Inst); Merck (Inst); MorphoSys (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen; Pfizer
 
Martin Görner
No Relationships to Disclose
 
Peter Staib
Stock and Other Ownership Interests - Novartis
Honoraria - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Incyte; Takeda
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; Incyte
Research Funding - Abbvie (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Ipsen
Other Relationship - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); BMS GmbH & Co. KG (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly Medical (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Orion Health (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Stemline Therapeutics (Inst); Takeda (Inst)
 
Hermann Einsele
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline Canada; Janssen; Novartis; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Novartis; Sanofi; Takeda
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Janssen
 
Michael Hundemer
Employment - MSD (I)
Consulting or Advisory Role - Becton Dickinson (Inst); BeiGene (Inst)
Research Funding - Alexion Pharmaceuticals (Inst); BeiGene (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - BeiGene (Inst)
 
Axel Benner
No Relationships to Disclose
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; I-Med Institute; Medupdate; Merck KGaA; Merck Sharp Dohme; Roche
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; Daiichi Sankyo Europe GmbH; Janssen-Cilag GmbH; Lindis Biotech; Merck Sharp & Dohme; Oncology Drug Consult (ODC); Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CPT Cellex Patient Treatment (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycostem (Inst); Glycotope GmbH (Inst); immatics (Inst); Incyte (Inst); IO Biotech (Inst); Ipsen (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier/Pfizer (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Janssen-Cilag; Merck Serono; Sanofi
 
Hartmut Goldschmidt
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Oncopeptides; Pfizer; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); GlaxoSmithKline; Janssen-Cilag (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); GlycoMimetics Inc. (Inst); Heidelberg Pharma (Inst); Janssen Research & Development (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen-Cilag; Oncopeptides; Pfizer; Sanofi
 
Katja Weisel
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen (Inst); Janssen-Cilag; Karyopharm Therapeutics; Novartis; Oncopeptides; Pfizer; Roche; Sanofi; Stemline Therapeutics; Takeda
Consulting or Advisory Role - Abbvie; Amgen; BeiGene; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Menarini; Oncopeptides; Regeneron; Roche; Sanofi; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Menarini; Takeda